WuXi Biologics stated that it is "steadily achieving" growth in both revenue and profit for the fiscal year 2025

華爾街見聞
2026.01.11 23:45
根據香港交易所 1 月 11 日的文件顯示，藥明生物技術有限公司將在年度醫療健康大會上進行簡報，該公司穩步實現 2025 財年目標——收入和利潤雙雙增長。該公司 2026 財年業務增長勢頭繼續，受研究服務、藥物開發和生產業務所支撐。研究服務業務延續 2024 年強勁勢頭至 2025 年， CD3 TCE 分子合作加速，平台迎來戰略節點。2025 年合作項目的潛在里程碑付款總額高達 40 億美元以上。
Source: 華爾街見聞 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.